

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	FECAL BACTERIOTHERAPY
Policy Number	2.01.48
Category	Technology Assessment
Effective Date	08/16/12
Revised Date	08/15/13, 07/17/14, 07/16/15, 06/16/16, 06/15/17, 09/20/18, 09/19/19
Product Disclaimer	<ul style="list-style-type: none"> • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit. • If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

- I. Based upon our criteria and assessment of peer-reviewed literature, fecal bacteriotherapy has been medically proven to be effective and is considered **medically appropriate** for the treatment of recurrent clostridium difficile infection (CDI) when ALL of the following have been met:
 - A. Patient has had at least three (3) episodes of recurrent CDI despite the standard antibiotic therapy;
 - B. Patient is not immunocompromised; AND
 - C. The appropriate donor stool screening has been completed (see guidelines below).
- II. Based upon our criteria and assessment of the peer-reviewed literature, fecal bacteriotherapy has not been medically proven to be effective and is considered **investigational** for all other indications, including but not limited to, the first line treatment for CDI or the treatment of inflammatory bowel disease.

Refer to Corporate Medical Policy #11.01.03 regarding Experimental or Investigational Services.

POLICY GUIDELINES

- I. The most appropriate donor is a spouse, significant other, or first degree relative if possible. Donor stool screening should follow the FDA guidelines for biologic donors and include at least the following:
 - A. Screening for transmissible bloodborne diseases or other diseases associated with microflora changes (e.g., irritable bowel syndrome, constipation);
 - B. Screening for transmissible pathogens;
 - C. Donor has not had antibiotic therapy for at least three months previous to donation; and
 - D. Donor should not ingest foods that the patient is allergic to.
- II. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

The recurrence of Clostridium difficile infection (CDI) is one of the most difficult and increasingly common challenges associated with the infection. An initial incidence of CDI is followed by a relapse within 30 days in about 20 – 30 % of cases, and the risk of recurrence doubles after two or more occurrences. Older age, intercurrent antibiotic use for non- C. difficile indications, renal insufficiency, immune deficiency and antacid medications are some of the known risk factors for recurrence. The presence of just three clinical criteria: age greater than 65 years, severe disease, and continued use of antibiotics after treating the initial CDI episode, are predictive of an almost 90 % relapse rate. It is now recognized that the presence of normal, healthy, intestinal microbiota offers protection against CDI. Conversely, severe disruption of normal intestinal microbiota by repeated cycles of antibiotics, including metronidazole and vancomycin that are used to treat CDI, is likely one of the major reason for its recurrence.

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 2 of 7

The American College of Gastroenterology published guidelines for the diagnosis, treatment, and prevention of CDI in 2013. Highlights of the guidelines for the treatment of CDI are as follows: Patients with mild-to-moderate CDI should be treated with metronidazole 500 mg orally three times per day for 10 days (Strong recommendation, high-quality evidence); Patients with severe CDI should be treated with vancomycin 125 mg four times daily for 10 days (Conditional recommendation, moderate-quality evidence); Failure to respond to metronidazole therapy within 5 – 7 days should prompt consideration of a change in therapy to vancomycin at standard dosing (Strong recommendation, moderate-quality evidence); For mild-to-moderate CDI in patients who are intolerant/allergic to metronidazole and for pregnant /breastfeeding women, vancomycin should be used at standard dosing. (Strong recommendation, high-quality evidence); In patients in whom oral antibiotics cannot reach a segment of the colon, such as with Hartman’s pouch, ileostomy, or colon diversion, vancomycin therapy delivered via enema should be added to treatments above until the patient improves (Conditional recommendation, low-quality evidence). Vancomycin delivered orally (125 mg four times per day) plus intravenous metronidazole (500 mg three times a day) is the treatment of choice in patients with severe and complicated CDI who have no significant abdominal distention (Strong recommendation, low-quality evidence). Vancomycin delivered orally (500 mg four times per day) and per rectum (500 mg in a volume of 500 ml four times a day) plus intravenous metronidazole (500 mg three times a day) is the treatment of choice for patients with complicated CDI with ileus or toxic colon and /or significant abdominal distention (Strong recommendation, low-quality evidence). The first recurrence of CDI can be treated with the same regimen that was used for the initial episode. If severe, however vancomycin should be used. The second recurrence should be treated with a pulsed vancomycin regimen (Conditional recommendation, low-quality evidence). If there is a third recurrence after a pulsed vancomycin regimen, fecal microbiota transplant (FMT) should be considered (Conditional recommendation, moderate-quality evidence).

Fecal bacteriotherapy, also known as fecal microbiota therapy (FMT) and fecal transplantation, involves restoration of normal bowel flora by introducing bacterial flora by the infusion of a stool preparation obtained from of a healthy stool donor, who in most instances is a close relative. Fecal bacteriotherapy involves single to multiple infusions and can be carried out via different routes such as nasogastric tube, enema, or more commonly by through a colonoscope. The proposed benefits of fecal bacteriotherapy include the restoration of the colonic flora to its natural state by replacing the missing Bacteroidetes and Firmicutes species, the eradication of *C. difficile*, and the resolution of the debilitating clinical symptoms such as diarrhea, cramping and urgency.

The principal potential risk associated with fecal bacteriotherapy is transmission of contagious agents contained in the donor stool. There are risks of transmitting agents that do not cause a disease immediately after transplantation, but may complicate the treatment of the patient in the future. The fecal transplant material needs to be prepared and administered in a clinic or hospital environment to ensure that necessary precautions are followed and the donor stool must be appropriately screened for infectious diseases and pathogens. The FDA guidelines for donors of human cells, tissues and cellular and tissue-based products should be reviewed. Stool testing would include: *C difficile* toxin; routine bacterial culture for enteric pathogens; fecal *Giardia* antigen; fecal *Cryptosporidium* antigen; acid- fast stain for *Cyclospora* and *Isospora* (acid-fast for *cryptosporidium* if no antigen is available); ova and parasites; and *Helicobacter pylori* fecal antigen. Serologic testing should include the following: HIV (type I and II); Testing for hepatitis A, B and C; and rapid plasma regain (PR) and florescent treponemal antibody absorption test (FTA-ABS) for syphilis.

RATIONALE

Based on the outcomes published from case series/case reports, and one randomized controlled trial, fecal bacteriotherapy is a highly effective therapy for refractory, recurrent *C Difficile* infection when standard treatments have failed. Overall, fecal bacteriotherapy resulted in resolution for 92% of patients (89% after a single treatment). Safety-wise, relapses and deaths after fecal bacteriotherapy were relatively uncommon; however, longer-term outcomes are needed to ensure these complication rates do not increase. Fecal bacteriotherapy as a first line therapy for *C Difficile* infection as not been studied sufficiently as the participants in published studies thus far have been patient who have failed multiple antibiotic regimens.

FMT has been shown to have some effect in alleviating symptoms in other difficult-to-treat conditions such as irritable bowel syndrome, and inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. The majority of studies in these diseases mainly consist of case series, case reports, and cohort studies. While outcome data are promising, there is insufficient evidence at this time to implement FMT as a treatment regimen. Additional RCTs and longer-term studies

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 3 of 7

are still needed to determine efficacy and safety profiles for patients with diseases other than recurrent C Difficile infection.

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT Codes

Code	Description
44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen

Copyright © 2019 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen

ICD10 Codes

Code	Description
A04.71-A04.72	Enterocolitis due to Clostridium difficile (code range)

REFERENCES

Agency for Healthcare Research and Quality. Comparative effectiveness review. No 31. Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection. 2011 Dec.

[https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/c-diff-infections_research.pdf] accessed 8/21/19.

Allegretto JR, et al. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile infection. *J Vis Exp* 2014 Dec 8;(94).

*Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. *Anaerobe* 2009 Dec;15(6):285-9.

BlueCross BlueShield Association. Fecal microbiota transplantation. Medical Policy Reference Manual Policy #2.01.92. 2018 Nov 08.

*Borody TJ, et al. Fecal microbiota transplantation: current status and future directions. *Expert Rev Gastroenterol Hepatol* 2011 Dec;5(6):653-5.

*Brandt LJ, et al. Fecal microbiota transplantation for recurrent clostridium difficile infection. *J Clin Gastroenterol* 2011 Nov;45 Suppl:S159-67.

Cammarota G, et al. Fecal microbiota transplantation for the treatment of clostridium difficile infection: A systematic review. *J Clin Gastroenterol* 2014 Sep;48(8):693-702.

Cammarota G, et al. Randomized clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. *Aliment Pharmacol Ther* 2015 May;41(9):835-43.

Cao Y, et al. The value of fecal microbiota transplantation in the treatment of ulcerative colitis patients: a systematic review and meta-analysis. *Gastroenterol Res Pract* 2018 Apr 3;2018:5480961.

Chapman BC, et al. Fecal microbiota transplant in patients with clostridium difficile infection: a systematic review. *J Trauma Acute Care Surg* 2016 Oct;81(4):756-764.

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 4 of 7

*Cober ED, et al. Clostridium difficile infection in the “oldest” old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009 Dec;57(12):2386.

Cohen NA, et al. Fecal microbiota transplantation for Clostridium difficile-associated diarrhea. Isr Med Assoc J 2015 Aug;17(8):510-4.

Colman RJ, et al. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014 Dec;8(12):1569-81.

Costello SP, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther 2015 Oct;42(8):1011-8.

Costello SP, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 2019 Jan 15;321(2):156-164.

Di Bella S, et al. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother 2015 Apr;21(4):230-7.

Diorio C, et al. Guideline for the management of Clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. J Clin Oncol 2018 Sep 14. [Epub ahead of print]

Dodin M, et al. Faecal microbiota transplantation for Clostridium difficile infection. Int J Clin Pract 2014 Mar;68(3):363-8.

Drekonja D, et al. Fecal microbiota transplantation for Clostridium difficile infection: A systematic review. Ann Intern Med 2015 May 5;162(9):630-8.

Duarte-Chavez R, et al Early results of fecal microbial transplantation protocol implementation at a community-based university hospital. J Glob Infect Dis 2018 Apr-Jun;10(2):47-57

Emanuelsson F, et al. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 2014 Feb;46(2):89-97.

Fischer M, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015 Aug;42(4):470-6.

Fischer M, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016 Oct;22(10):2402-2409.

Food and Drug Administration Guidance for Industry: Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. 2007 Aug
[<https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/tissue/ucm091345.pdf>] accessed 8/21/19.

Furuya-Kanamori L, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol 2017 Feb;51(2):145-150.

*Grehan MJ, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010 Sep;44(8):551-61.

Haber SL, et al. Fecal microbiota transplantation for recurrent Clostridioides difficile infection. Am J Health Syst Pharm 2019 Jun 18;76(13):935-942.

Health Quality Ontario. Fecal microbiota therapy for clostridium difficile infection: a Health Technology Assessment. Ont Health Technol Assess Ser 2016 July 1;16(17):1-69.

Hirsh BE, et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsule for recurrent Clostridium difficile infection. BMC Infect Dis 2015 Apr 17;15(1):191.

Hota SS, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 2017 Feb 1;64(3):265-271.

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 5 of 7

- Hourigan SK, et al. Microbiome changes associated with sustained eradication of *Clostridium difficile* after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther 2015 Sep;42(6):741-52.
- Hui W, et al. Fecal microbiota transplantation for treatment of recurrent *C. difficile* infection: An updated randomized controlled trial meta-analysis. PLoS One 2019 Jan 23;14(1):e0210016.
- Ianiro G, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 2014 Oct;93(19):e97.
- Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory *Clostridium difficile* infection-single versus multiple infusions. Aliment Pharmacol Ther 2018 Jul;48(2):152-159.
- Imdad A, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018 Nov 13;11:CD012774.
- Keller JJ and Kuijper EJ. Treatment of recurrent and severe *Clostridium difficile* infection. Ann Rev Med 2015;66:378-86.
- Kelly, BJ. and Tebas, P. Clinical practice and infrastructure review of fecal microbiota transplantation for *Clostridium difficile* infection. CHEST 2018; 153(1):266-277.
- *Kelly CP, et al. *Clostridium difficile*- more difficult than ever. New Engl J Med 2008 Oct;359(8):1932-40.
- Kelly CR, et al. Fecal microbiota transplant for treatment of *Clostridium difficile* infection in immunocompromised patients. Am J Gastroenterol 2014 Jul;109(7):1065-71.
- Kelly CR, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms and outlook. Gastroenterol 2015 Jul;149(1):223-37.
- Kelly CR, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent *clostridium difficile* infection: a randomized trial. Ann Intern Med 2016 Nov 1;165(9):609-616.
- Khan MA, et al. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community-and hospital-acquired *Clostridium difficile* infection. Can J Gastroenterol Hepatol 2014 Sep;28(8):434-8.
- Khoruts A, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent *clostridium difficile* infection. Clin Gastroenterol hepatol 2016 Oct;14(10):1433-1438.
- Ko CW, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019;156(3):748-764.
- Kronman MP, et al. Fecal microbiota transplantation via nasogastric tube for recurrent *clostridium difficile* infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015 Jan;60(1):23-6.
- Lagier JC, et al. Dramatic reduction in *Clostridium difficile* ribotype 027-associated mortality with early fecal transplantation by nasogastric route: a preliminary report. Eur J Clin Microbiol Infect Dis 2015 Aug;34(8):1597-601.
- *Landy J, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011 Aug;34(4):409-15.
- Lee CH, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory *Clostridium difficile* infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014 Aug;33(8):1425-8.
- Lee CH, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent *Clostridium difficile* infection: a randomized clinical trial. JAMA 2016 Jan 12;315(2):142-9.
- Merenstein D, et al. Fecal Microbial therapy- promises and pitfalls. J Pediatr Gastroenterol Nutr 2014 Aug; 59(2): 157-161.

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 6 of 7

Moayyedi P, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterol 2015 Jul;149(1):102-9.

Mullish BH, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018 Nov;67(11):1920-1941.

National Institute for Health and Care Excellence (NICE). Faecal microbiota transplant for recurrent Clostridium difficile infection. Interventional procedure guidance 485. 2013 Apr 18 [<https://www.nice.org.uk/Guidance/IPG485>] accessed 8/21/19.

Oldfield EC, et al. Clinical update for the diagnosis and treatment of Clostridium difficile infection. W J Gastrointest Pharmacol Ther 2014 Feb 6;5(1):1-26.

Rossen NG, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol 2015 May 7;21(17):5359-71.

Rossen NG, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterol 2015 Jul;149(1):110-8.

Sartelli M, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019 Feb 28;14:8.

Sha S, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014 May;39(10):1003-32.

Shi Y, et al. Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS One 2016 June 13;11(6):e0157259.

Shogbesan O, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018 Sep 2;2018:1394379.

Singh S, et al. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019 Feb;156(3):769-808.e29.

Staley C, et al. Successful resolution of recurrent clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol 2017 Jun;112(6):940-947.

*Surawicz C, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013 Apr;108(4):479-98.

Sun D, et al. Fecal microbiota transplantation as a novel therapy for ulcerative colitis: a systematic review and meta-analysis. Medicine 2016 June;95(23):e3765.

Suskind DL, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 2015 Mar;21(3):556-63.

Tabbaa OM, et al. Long-term safety and efficacy of fecal microbiota transplantation in the treatment of Clostridium difficile infection in patients with and without inflammatory bowel disease: a tertiary care center's experience. Gastroenterology Res 2018 Dec;11(6):397-403.

Tariq R, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis 2019 Apr 8;68(8):1351-1358.

Uygun A, et al. Fecal microbiota transplantation is a rescue modality for refractory ulcerative colitis. Medicine 2017 April;96(16):e6479.

van Beurden, YH, et al Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Ther Adv Gastroenterol 2017;10(4):373-381

Varier RU, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2015 Apr;36(4):438-44.

Medical Policy: FECAL BACTERIOTHERAPY

Policy Number: 2.01.48

Page: 7 of 7

Wang S, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One 2016 Aug 16;11(8):e0161174.

Wei Y, et al. Fecal microbiota transplantation restores dysbiosis inpatients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect Dis 2015 Jul 11;15:265.

*Yoon SS, et al. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010 Sep;44(8):562-6.

Youngster I, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis 2014 Jun;58(11):1515-22.

Youngster I, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014 Nov 5;12(17):1772-8.

Zanella Terrier MC, et al. Recurrent Clostridium difficile infections: the importance of intestinal microbiota. World J Gastroenterol 2014 Jun 21;20(23):7416-23.

Zaninag H, et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015 Jan;60(1):181-5.

*Key Article

KEY WORDS

Fecal microbiota therapy (FMT), Fecal transfusion, Fecal transplant, Human probiotic infusion (HPI), Intestinal microbiota Transplantation (IMT), Microbiome, Stool transplant

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based upon our review, fecal bacteriotherapy is not addressed in National or regional CMS coverage determinations or policies.